Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-ICOX Regimen (Bevacizumab, Capecitabine, Oxaliplatin) in Advanced Colorectal Cancer
NCT00177307Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2005
- Primary completion
- Feb 2012
- Countries
- 1
- Sponsor
- University of Pittsburgh
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by University of Pittsburgh. Primary endpoint: Progression Free Survival at 27 months. Started Jan 2005; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Oxaliplatin, Capecitabine, and Bevacizumab
Bevacizumab 5 mg/kg q2w, Capecitabine 2500 mg/m2/d (d1-8 q2w), Oxaliplatin 85 mg/m2 (d1 q2w)
03
Who it enrols
Patients with untreated advanced colorectal cancer, measurable disease, ECOG 0-2, and adequate organ function. Excludes patients eligible for surgery, prior metastatic therapy, or prior oxaliplatin/bevacizumab.
04
Endpoints
Primary
Progression Free Survival
Secondary
Response Rate
Overall Survival
1-, 2-, and 3-year Overall Survival
Beyond the preview
Go deeper on NCT00177307.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177307.